drug candidates

With years of drug discovery and development expertise and proprietary bioinformatics capabilities to aid in the design and optimization of LNA-based drugs, Santaris Pharma A/S is uniquely positioned to rapidly identify appropriate RNA targets and subsequently generate optimally designed drugs for a range of diseases.

Leveraging its Drug Discovery Engine, Santaris Pharma A/S has been able to create an attractive in-house pipeline of innovative LNA-based drugs, with the ability to move from target selection to clinical trials in less than 18 months.

infectious diseases
cancer
metabolic disorders
rare genetic disorders